TY - JOUR
T1 - Enrichment of IGF-1R and PPARγsignalling pathways in orbital inflammatory diseases
T2 - steps toward understanding pathogenesis
AU - Verma, Rohan
AU - Choi, Dongseok
AU - Chen, Allison J.
AU - Harrington, Christina A.
AU - Wilson, David J.
AU - Grossniklaus, Hans E.
AU - Dailey, Roger A.
AU - Ng, John
AU - Steele, Eric A.
AU - Planck, Stephen R.
AU - Korn, Bobby S.
AU - Kikkawa, Don
AU - Czyz, Craig N.
AU - Foster, Jill A.
AU - Kazim, Michael
AU - Harris, Gerald J.
AU - Edward, Deepak P.
AU - Al-Hussain, Haila
AU - Maktabi, Azza M.Y.
AU - Alabiad, Chris
AU - Garcia, Armando
AU - Rosenbaum, James T.
N1 - Funding Information:
a coinvestigator on a study funded by Genentech to evaluate the use of rituximab for orbital inflammatory diseases. JTR, RAD, BSK, DOK, and GJH are consultants to Horizon Pharmaceuticals which manufactures teprotumumab. JTR receives research support from Horizon Pharmaceuticals.
Funding Information:
Funding This research was supported by funding from National Institutes of Health (NIH) USA Grants EY020249 (JTR) and an NIH/NEI Core Grant P30 EY010572. JTR receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust and Research to Prevent Blindness (no award number from these sources). The sponsors did not have any role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the manuscript for publication.
Publisher Copyright:
©
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Background Orbital inflammatory disease (OID) encompasses a wide range of pathology including thyroid-associated orbitopathy (TAO), granulomatosis with polyangiitis (GPA), sarcoidosis and non-specific orbital inflammation (NSOI), accounting for up to 6% of orbital diseases. Understanding the underlying pathophysiology of OID can improve diagnosis and help target therapy. Aims To test the hypothesis that shared signalling pathways are activated in different forms of OID. Methods In this secondary analysis, pathway analysis was performed on the previously reported differentially expressed genes from orbital adipose tissue using patients with OID and healthy controls who were characterised by microarray. For the original publications, tissue specimens were collected from oculoplastic surgeons at 10 international centres representing four countries (USA, Canada, Australia and Saudi Arabia). Diagnoses were independently confirmed by two masked ocular pathologists (DJW, HEG). Gene expression profiling analysis was performed at the Oregon Health & Science University. Eighty-three participants were included: 25 with TAO, 6 with orbital GPA, 7 with orbital sarcoidosis, 25 with NSOI and 20 healthy controls. Results Among the 83 subjects (mean (SD) age, 52.8 (18.3) years; 70% (n=58) female), those with OID demonstrated perturbation of the downstream gene expressions of the IGF-1R (MAPK/RAS/RAF/MEK/ERK and PI3K/Akt/mTOR pathways), peroxisome proliferator-activated receptor-γ(PPAR 3), adipocytokine and AMPK signalling pathways compared with healthy controls. Specifically, GPA samples differed from controls in gene expression within the insulin-like growth factor-1 receptor (IGF-1R, PI3K-Akt (p=0.001), RAS (p=0.005)), PPARγ(p=0.002), adipocytokine (p=0.004) or AMPK (p=<0.001) pathways. TAO, sarcoidosis and NSOI samples were also found to have statistically significant differential gene expression in these pathways. Conclusions Although OID includes a heterogenous group of pathologies, TAO, GPA, sarcoidosis and NSOI share enrichment of common gene signalling pathways, namely IGF-1R, PPAR 3, adipocytokine and AMPK. Pathway analyses of gene expression suggest that other forms of orbital inflammation in addition to TAO may benefit from blockade of IGF-1R signalling pathways.
AB - Background Orbital inflammatory disease (OID) encompasses a wide range of pathology including thyroid-associated orbitopathy (TAO), granulomatosis with polyangiitis (GPA), sarcoidosis and non-specific orbital inflammation (NSOI), accounting for up to 6% of orbital diseases. Understanding the underlying pathophysiology of OID can improve diagnosis and help target therapy. Aims To test the hypothesis that shared signalling pathways are activated in different forms of OID. Methods In this secondary analysis, pathway analysis was performed on the previously reported differentially expressed genes from orbital adipose tissue using patients with OID and healthy controls who were characterised by microarray. For the original publications, tissue specimens were collected from oculoplastic surgeons at 10 international centres representing four countries (USA, Canada, Australia and Saudi Arabia). Diagnoses were independently confirmed by two masked ocular pathologists (DJW, HEG). Gene expression profiling analysis was performed at the Oregon Health & Science University. Eighty-three participants were included: 25 with TAO, 6 with orbital GPA, 7 with orbital sarcoidosis, 25 with NSOI and 20 healthy controls. Results Among the 83 subjects (mean (SD) age, 52.8 (18.3) years; 70% (n=58) female), those with OID demonstrated perturbation of the downstream gene expressions of the IGF-1R (MAPK/RAS/RAF/MEK/ERK and PI3K/Akt/mTOR pathways), peroxisome proliferator-activated receptor-γ(PPAR 3), adipocytokine and AMPK signalling pathways compared with healthy controls. Specifically, GPA samples differed from controls in gene expression within the insulin-like growth factor-1 receptor (IGF-1R, PI3K-Akt (p=0.001), RAS (p=0.005)), PPARγ(p=0.002), adipocytokine (p=0.004) or AMPK (p=<0.001) pathways. TAO, sarcoidosis and NSOI samples were also found to have statistically significant differential gene expression in these pathways. Conclusions Although OID includes a heterogenous group of pathologies, TAO, GPA, sarcoidosis and NSOI share enrichment of common gene signalling pathways, namely IGF-1R, PPAR 3, adipocytokine and AMPK. Pathway analyses of gene expression suggest that other forms of orbital inflammation in addition to TAO may benefit from blockade of IGF-1R signalling pathways.
UR - http://www.scopus.com/inward/record.url?scp=85101716456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101716456&partnerID=8YFLogxK
U2 - 10.1136/bjophthalmol-2020-318330
DO - 10.1136/bjophthalmol-2020-318330
M3 - Article
C2 - 33637620
AN - SCOPUS:85101716456
SN - 0007-1161
VL - 106
SP - 1012
EP - 1017
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 7
ER -